Brief: Centessa Expects To Incur Costs Of About $6 Mln To $8 Mln Relating To Lixivaptan Program Wind-Down Activities, Reduction In Headcount

Centessa Pharmaceuticals

02/06/2022 11:45

June 2 (Reuters) - Centessa Pharmaceuticals PLC  260y.F :
    * CENTESSA - EXPECT TO INCUR COSTS OF ABOUT $6 MILLION TO $8
MILLION RELATING TO LIXIVAPTAN PROGRAM WIND-DOWN ACTIVITIES,
REDUCTION IN HEADCOUNT
    * CENTESSA-EXPECT TO INCUR COSTS RELATING TO LIXIVAPTAN
PROGRAM
WIND-DOWN ACTIVITIES, REDUCTION IN HEADCOUNT,EXPECTED TO BE
INCURRED IN 2022

Source text for Eikon: [https://bit.ly/3PPQQV3]
Further company coverage:  260y.F 

 ((Reuters.Briefs@thomsonreuters.com;))